Journal article

Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens

  • Dobias, Jan French INSERM European Unit (LEA/IAME), and National Reference Center for Emerging Antibiotic Resistance and Emerging Antibiotic Resistance Unit, University of Fribourg, Switzerland - Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland
  • Dénervaud Tendon, Valérie French INSERM European Unit (LEA/IAME), and National Reference Center for Emerging Antibiotic Resistance and Emerging Antibiotic Resistance Unit, University of Fribourg, Switzerland - Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland
  • Poirel, Laurent French INSERM European Unit (LEA/IAME), and National Reference Center for Emerging Antibiotic Resistance and Emerging Antibiotic Resistance Unit, University of Fribourg, Switzerland - Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland
  • Nordmann, Patrice French INSERM European Unit (LEA/IAME), and National Reference Center for Emerging Antibiotic Resistance and Emerging Antibiotic Resistance Unit, University of Fribourg, Switzerland - Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland - Institute for MicrobiologyUniversity of Lausanne and University Hospital Centre, Lausanne, Switzerland
Show more…
    26.07.2017
Published in:
  • European Journal of Clinical Microbiology & Infectious Diseases. - 2017, p. 1–9
English The novel siderophore cephalosporin cefiderocol (S-649266) with potent activity against Gram-negative pathogens was recently developed (Shionogi & Co., Ltd.). Here, we evaluated the activity of this new molecule and comparators against a collection of previously characterized Gram-negative isolates using broth microdilution panels. A total of 753 clinical multidrug-resistant Gram-negative isolates collected from hospitals worldwide were tested against cefiderocol and antibiotic comparators (ceftolozane–tazobactam [CT], meropenem [MEM], ceftazidime [CAZ], ceftazidime–avibactam [CZA], colistin [CST], aztreonam [ATM], amikacin [AMK], ciprofloxacin [CIP], cefepime [FEP], and tigecycline [TGC]) for their susceptibility. The collection included Escherichia coli (n = 164), Klebsiella pneumoniae (n = 298), Enterobacter sp. (n = 159), Pseudomonas aeruginosa (n = 45), and Acinetobacter baumannii (n = 87). Resistance mechanisms included producers of carbapenemases and extended-spectrum β-lactamases (ESBLs). In addition, a series of colistin-resistant enterobacterial isolates (n = 74), including 15 MCR-1 producers, were tested. The MIC90 of cefiderocol was 2 mg/L, while those of comparative drugs were >64 mg/L for CT, MEM, CAZ, CZA, and AMK, >32 mg/L for ATM, >16 mg/L for FEP, 8 mg/L for CST, and 2 mg/L for TGC. The MIC50 of cefiderocol was 0.5 mg/L, while those of other drugs were >64 mg/L for CAZ, 64 mg/L for CT, >32 mg/L for ATM, >16 mg/L for FEP, 8 mg/L for MEM and AMK, >4 mg/L for CIP, 1 mg/L for CZA, 0.5 mg/L for TGC, and 0.5 mg/L for CST. Only 20 out of 753 strains showed MIC values of cefiderocol ≥8 μg/mL. Compared to the other drugs tested, cefiderocol was more active, with the exception of colistin and tigecycline showing equivalent activity against certain subgroups of bacteria.
Faculty
Faculté des sciences et de médecine
Department
Médecine 3ème année
Language
  • English
Classification
Biology
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/305999
Statistics

Document views: 19 File downloads:
  • nor_ans.pdf: 5